Pacific Biosciences of California (DB:P09) - Aandelenkoers, Nieuws & Analyse

P09 Overzicht aandelen

Pacific Biosciences of California, Inc. ontwerpt, ontwikkelt en produceert sequencingoplossingen om genetisch complexe problemen op te lossen. Meer informatie

P09 fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

Verhandeld tegen 55.1% onder onze schatting van de reële waarde

De omzet zal naar verwachting met 19.52% per jaar groeien

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Pacific Biosciences of California, Inc. Concurrenten

Evotec

XTRA:EVT

€1.5b

Gerresheimer

XTRA:GXI

€2.6b

SCHOTT Pharma KGaA

XTRA:1SXP

€4.2b

Sartorius

XTRA:SRT3

€14.1b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Pacific Biosciences of California
Historische aandelenkoersen
Huidige aandelenkoers	US$1.86
52 Week Hoogtepunt	US$9.40
52 Week Laag	US$1.05
Bèta	2.01
11 maand verandering	0.41%
3 maanden verandering	24.67%
1 Jaar Verandering	-69.01%
33 jaar verandering	-91.70%
5 jaar verandering	-59.26%
Verandering sinds IPO	-84.52%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	P09	DE Life Sciences	DE Markt
7D	-22.3%	1.7%	-0.2%
1Y	-69.0%	9.0%	7.8%

Rendement versus industrie: P09 presteerde slechter dan de German Life Sciences -sector, die het afgelopen jaar een rendement van 9 % opleverde.

Rendement versus markt: P09 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 7.8 % opleverde.

Prijsvolatiliteit

Is P09's price volatile compared to industry and market?
P09 volatility
P09 Average Weekly Movement	19.1%
Life Sciences Industry Average Movement	6.1%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.7%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van P09 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 19% ) van P09 is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2000	796	Christian O. Henry	www.pacb.com

Pacific Biosciences of California, Inc. ontwerpt, ontwikkelt en produceert sequencingoplossingen om genetisch complexe problemen op te lossen. Het bedrijf levert sequencing systemen; verbruiksartikelen, waaronder single molecule real-time (SMRT) technologie; long-red sequencing; en verschillende reagenskits ontworpen voor specifieke workflows, zoals voorbereidingskits om DNA om te zetten in SMRTbell dubbelstrengs DNA-bibliotheekformaten, waaronder moleculair biologische reagentia, zoals ligase, buffers en exonucleases. Het biedt ook bindingskits, zoals gemodificeerd DNA-polymerase dat wordt gebruikt om SMRTbell-bibliotheken aan het polymerase te binden ter voorbereiding op sequentiebepaling; en sequentiebepalingskits omvatten reagentia die nodig zijn voor real-time sequentiebepaling op instrumenten, waaronder de gefosfolinkte nucleotiden.

Pacific Biosciences of California, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Pacific Biosciences of California zich tot de beurswaarde?
P09 fundamentele statistieken
Marktkapitalisatie	€514.22m
Inkomsten(TTM)	-€373.86m
Inkomsten(TTM)	€164.20m

3.1x

P/S-verhouding

-1.4x

Koers/Winstverhouding

Is P09 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
P09 resultatenrekening (TTM)
Inkomsten	US$173.15m
Kosten van inkomsten	US$118.91m
Brutowinst	US$54.23m
Overige uitgaven	US$448.47m
Inkomsten	-US$394.24m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.44
Brutomarge	31.32%
Nettowinstmarge	-227.69%
Schuld/Eigen Vermogen Verhouding	197.1%

Hoe presteerde P09 op de lange termijn?

Bekijk historische prestaties en vergelijking

P09 Overzicht aandelen

Beloningen

Risicoanalyse

Pacific Biosciences of California, Inc. Concurrenten

XTRA:EVT

€1.5b

XTRA:GXI

€2.6b

XTRA:1SXP

€4.2b

XTRA:SRT3

€14.1b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 3Q 2023)

PacBio Unveils the Vega System

PacBio Announces SPRQ Chemistry for Revio Sequencing Systems

Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024

President recently sold €155k worth of stock

Chief Operating Officer recently sold €57k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 3Q 2023)

PacBio Unveils the Vega System

PacBio Announces SPRQ Chemistry for Revio Sequencing Systems

Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024

President recently sold €155k worth of stock

Chief Operating Officer recently sold €57k worth of stock

Pacific Biosciences of California, Inc. Reports Goodwill Impairment for the Second Quarter Ended June 30, 2024

Pacific Biosciences of California, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.36 loss in 1Q 2023)

Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions

Insider recently bought €162k worth of stock

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

President recently sold €445k worth of stock

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale

Pacific Biosciences of California, Inc. to Report Q4, 2023 Results on Feb 15, 2024

PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions

Chief Operating Officer recently sold €221k worth of stock

Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board

PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders

Third quarter 2023 earnings released: US$0.26 loss per share (vs US$0.34 loss in 3Q 2022)

Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee

Pacific Biosciences of California, Inc. Appoints David Meline to its Board of Directors

Pacific Biosciences of California, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Pacbio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

President recently sold €918k worth of stock

Chief Operating Officer recently sold €263k worth of stock

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for approximately $110 million.

Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.32 loss in 2Q 2022)

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for $110 million.

Pacific Biosciences of California, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Now 25% undervalued

Pacific Biosciences of California, Inc. Announces Board Changes

VP & Chief Accounting Officer recently sold €60k worth of stock

Insufficient new directors

Full year 2022 earnings released: US$1.40 loss per share (vs US$0.89 loss in FY 2021)

PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions

Pacific Biosciences of California, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Insufficient new directors

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022

Pacific Biosciences of California, Inc. Announces Board Appointments

Pacific Biosciences of California, Inc. Withdraws its Financial Guidance

Pacific Biosciences of California, Inc. to Report Q3, 2022 Results on Nov 07, 2022

PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery

PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing

Chief Financial Officer recently sold €75k worth of stock

PacBio Unveils A New Method for Comprehensive, Genome-Wide Tandem Repeat Analysis

Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.21 loss in 2Q 2021)

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year 2022

Pacific Biosciences of California, Inc. Appoints Jeff Eidel as Chief Commercial Officer, Effective August 16, 2022

Pacific Biosciences of California, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Pacific Biosciences of California, Inc. Announces Management Changes

First quarter 2022 earnings released: US$0.37 loss per share (vs US$0.45 loss in 1Q 2021)

Insufficient new directors